Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2011, XXXI/185: 270-273 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2011, XXXI/185: 270-273

Title: Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease

Authors: Piesiak P., Brzecka A., Kosacka M., Passowicz-Muszyńska E., Dyła T., Jankowska R.

More details

02/185

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease


Piesiak P., Brzecka A., Kosacka M., Passowicz-Muszyńska E., Dyła T., Jankowska R.

Medical University of Wrocław, Poland, Department of Pneumonology and Lung Neoplasmas

Chronic obstructive pulmonary disease (COPD) is characterized by the progressive destruction of the extracellular matrix of the lung. Matrix metalloproteinases (MMPs) and their inhibitors, especially tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), play a central role in the lung remodeling in COPD. Their concentrations in the sputum and bronchoalveolar lavage are considered as a sign of the local inflammation in COPD patients.
The aim of the study
was to evaluate of the MMP-9 and TIMP-1 serum concentration in COPD patients with respect to the correlation with a systemic inflammatory process.
Material and methods
. Thirty six COPD patients (29 male and 7 female) were enrolled into the study. Age-matched, healthy 15 subjects (11 male and 4 female) were selected as a control group. Serum levels of MMP-9, TIMP-1 and CRP were measured. The preand post-bronchodilator forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio were determined. The Spearman correlation was performed.
Results
. The serum MMP-9 concentration was significantly higher in the COPD patients than that in the control group (COPD: 194.8±129.1 ng x ml-1; control subjects: 11.7±2.1 ng x ml-1; p < 0.001). The serum concentration of CRP was significantly higher in the COPD patients than that in the control group (COPD: 14.3±6.3 ng x ml-1; control subjects: 6.2±2.8 ng x ml-1; p < 0.001). There was statistically significant correlation between the MMP-9 concentration and the CRP level in the serum of patients with COPD (p < 0.01; r = 0.45). There were no significant differences in the serum TIMP-1 concentrations between the control group and COPD patients. There was statistically significant, negative correlation between the FEV1 % of predicted value and the MMP-9 concentration (p = 0.03; r = -0.43).
Conclusions
. MMP-9 may play an important role in the systemic inflammatory process in COPD. The serum concentrations of MMP-9 correlate with the stage of COPD.

Key words: CRP, chronic obstructive pulmonary disease, metalloproteinase- 9, tissue inhibitor of metalloproteinase-1

Pol. Merk. Lek., 2011, XXXI, 185, 270